Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $52.78 Consensus Target Price from Brokerages

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has been given an average rating of “Moderate Buy” by the eleven ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, five have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $53.3333.

A number of brokerages have recently commented on ARWR. The Goldman Sachs Group raised their target price on shares of Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the company a “neutral” rating in a research note on Thursday, November 20th. Bank of America increased their price target on Arrowhead Pharmaceuticals from $42.00 to $62.00 and gave the company a “buy” rating in a report on Monday. Royal Bank Of Canada boosted their price objective on Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 19th. B. Riley raised Arrowhead Pharmaceuticals to a “strong-buy” rating in a research report on Monday, August 11th. Finally, Morgan Stanley increased their target price on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 26th.

Arrowhead Pharmaceuticals Stock Down 0.6%

Shares of NASDAQ:ARWR opened at $64.66 on Tuesday. The stock has a 50-day simple moving average of $41.44 and a 200-day simple moving average of $27.16. The stock has a market capitalization of $8.78 billion, a P/E ratio of -808.15 and a beta of 1.28. Arrowhead Pharmaceuticals has a 1 year low of $9.57 and a 1 year high of $67.14. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 20,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total value of $700,000.00. Following the transaction, the insider owned 212,122 shares in the company, valued at $7,424,270. The trade was a 8.62% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Mauro Ferrari sold 8,750 shares of the firm’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $56.39, for a total value of $493,412.50. Following the sale, the director owned 68,764 shares of the company’s stock, valued at $3,877,601.96. This represents a 11.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 43,750 shares of company stock worth $1,643,413 in the last quarter. Insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ARWR. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Arrowhead Pharmaceuticals during the 1st quarter worth approximately $174,000. XTX Topco Ltd acquired a new stake in shares of Arrowhead Pharmaceuticals during the first quarter worth approximately $133,000. Vanguard Group Inc. increased its stake in shares of Arrowhead Pharmaceuticals by 8.4% in the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock worth $168,201,000 after buying an additional 1,018,273 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Arrowhead Pharmaceuticals by 1.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 1,035,290 shares of the biotechnology company’s stock valued at $13,190,000 after acquiring an additional 17,570 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board bought a new position in Arrowhead Pharmaceuticals during the 1st quarter valued at $583,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.